



September 19, 2017

Diabeloop S.A. , the company developing the French Artificial Pancreas raises € 13.5m meeting a new milestone toward commercialization planned in 2018

In order to accelerate its development, Diabeloop S.A. has just raised € 13.5 million of funding in equity, debt, and public subsidies from major investors. This funding will enable the company to meet major upcoming milestones, mainly the CE marking, the completion of complementary clinical studies, as well as the commercial launch of the device.

The Diabeloop Artificial Pancreas is an electronic device that acts as a substitute to the failing pancreas, and constitutes a major clinical breakthrough. It will be made available to doctors and patients in the course of 2018.

A recent study demonstrates the superiority of this electronic device with regards to an open-loop insulin pump for patients of type 1 diabetes during physical activity, high-calorie meals, and during rest. The Artificial Pancreas is being tested in a clinical trial with 60 patients. The first randomly assigned patients have already worn the device 3 months at home. The first batches of data confirm the excellent results obtained in the previous study. In France, 50 percent of people affected by type 1 diabetes have difficulty balancing their blood sugar levels.

Strong financial partners to accelerate development

Diabeloop SA, a startup founded by CERITD in 2015 to pursue an Artificial Pancreas project supported by the French Federation of Patients of Diabetes (AFD), raised € 13.5 million in new funding in July to accelerate its development with the aim of commercializing its Artificial Pancreas in 2018.

ALIAD, the venture capital investor of the Air Liquide Group and the investment funds managed by Supernova Invest, Sofimac Partners, Kréaxi, as well as by Crédit Agricole Sud Rhône Alpes Capital and Crédit Agricole des Savoie Capita (regional investment funds of Crédit Agricole) have subscribed to a capital increase of € 7.5 million.

Diabeloop's management and its historic shareholder, CERITD, who are convinced of the future success of the project, have also decided to invest again by participating in this capital increase.

Diabeloop S.A. has also obtained additional funding:

- from the French public investment bank BPI France through the PSPC Mellidem,
- and from Crédit Agricole Sud Rhône Alpes and Banque Populaire Auvergne Rhône Alpes

This funding will enable Diabeloop to continue the development of its system, to complete the first stages of the commercialization of its Artificial Pancreas in France and in Europe after obtaining the

CE marking, to undertake the studies to obtain the reimbursement of the treatment by health insurances as well as to start the FDA approval process for a launch in the United States.

Much progress has been made since the launch of the project in 2011 by CERITD (Center for Research and the Intensification of the treatment of diabetes) in partnership with the Leti, an institute of CEA Tech, and a world player in microelectronics and micro / nanotechnologies.

In July 2015, in the light of the positive results of the first studies, Diabeloop SA and CEA-Leti created a joint laboratory to develop the "closed-loop" Diabeloop system, which delivers insulin automatically according to the blood glucose measured in real time by a sensor. With an "open loop" system, the patient must decide for himself/herself the dose of insulin to be injected.

The latest study, carried out in France in 2016, proved the interest of Diabeloop by comparison with an open loop (sensor + insulin pump), in these delicate situations¹.

*"With the success of this fundraising round, the Diabeloop project now has valuable financial partners. The investment of Air Liquide Group through ALIAD, as well as the investments from Bpifrance and our other partners, enable us to prepare the market launch next year in the best of conditions," says **Marc Julien, Diabeloop co-CEO.***

A clinical study of 60 patients for the CE marking

The system's effectiveness having been confirmed by the 2016 study, the next step is to obtain the CE marking of the Diabeloop system, a required step for commercialization in Europe.

A large comparative cross-over* trial of 60 patients in 12 French hospitals was launched in May. During three months, half of the patients - who were randomly selected - were treated at home with Diabeloop and the other half with their usual (portable open-loop insulin pump) system. They were monitored remotely by caregivers and with a visit to the hospital every two to three weeks. The first part of this study is reaching completion. Its second stage will be launched before the end of the year, integrating the lessons learned this summer. This "real life" study will also test the messages embedded in a proprietary remote monitoring platform and appraise the security of the system.

Diabeloop will carry out a one-year comparative study to demonstrate the medical and economic superiority of Diabeloop compared to existing treatments in order to obtain reimbursement of the device.

*"The algorithm at the heart of the system is continuously optimized by the researchers, and the user-friendliness of the interface has been further improved with patient groups," says **Erik Huneker, CEO and co-founder of Diabeloop.** "The success of the project stems from the close collaboration between CERITD and CEA-Leti, the early involvement of our industrial partners, and from the participation of doctors from the 12 participating university hospitals, and patients".*

* The cross-over trial uses patients as their own control groups. All patients receive the treatment under investigation and the control treatment in a random order



About Diabeloop (France)

The Diabeloop project began in 2011 with the aim of developing an Artificial Pancreas to improve the treatment of patients with Type 1 diabetes. The closed loop technology of Diabeloop SA has been evaluated in clinical trials at the hospital and will be evaluated this year, as part of the joint laboratory with CEA-Leti, with patients at home.

The company incorporated in 2015, and is based in Grenoble, France. Guillaume Charpentier is Chairman, Erik Huneker is CEO, and Marc Julien co-CEO. Follow us on www.diabeloop.fr and @diabeloop

About CERITD (France)

CERITD (Center for Research and the Intensification of the treatment of diabetes) is a nonprofit devoted to the treatment and

¹ Y. Reznick & all - Diabeloop closed-loop does better than sensor-Augmented pump on blood glucose control during 3 days with either intensive physical exercises, gastronomic dinners or rest in T1D - 2016

research on diabetes. It provides 1,200 patients in 5 centers in France, with a network of nurses and specialized practitioners. In addition to its activities as a clinical trial developer in the field of diabetes treatment, CERITD holds a unique position through a delegation of prescription contract for its nurses and maintains strong relationships with the regulatory authorities. Guillaume Charpentier, President of CERITD, has a long experience in the management of diabetes and diabetes research. In partnership with Voluntas. CERITD also created Diabeo, a connected insulin dose recommendation device launched by Sanofi. The Descent program, another CERITD flagship program conducted in collaboration with the geneticists of the Pasteur Institute in Lille (Pr P. Froguel), aims to create a diagnostic tool for the prediction of type 2 diabetes among the descendants of people suffering from this disease.



About ALIAD

ALIAD, the venture capital investor of the Air Liquide group, is responsible for taking minority shareholdings in innovative technological start-ups related to energy transition, healthcare and digital. ALIAD is positioning itself on the technologies of the future by helping startups to develop, through its industrial and technological experience, and its knowledge of customers throughout the world. These investments are accompanied by the establishment of privileged R&D and / or business agreements between these young companies and the other entities of the Group.
Contact: Marc David, Investment Director



About Crédit Agricole Sud Rhône Alpes Capital and Crédit Agricole des Savoie Capital :

CASRA Capital and CADS Capital are private equity funds set up by Crédit Agricole Sud Rhône Alpes and Crédit Agricole de Savoie to meet the need for capital support for companies in their territories at key stages of their development.

These funds are local investment companies and key players in the region that support entrepreneurs in innovation, development or business takeover projects, with an ideal of sustainable partnership.

Contact: sabrina.kouidri@ca-alpes-developpement.fr



About Kréaxi

KREAXI was born from the merger between Rhône-Alpes Création and Banexi Ventures Partners, and became one of France's leading venture capital providers, raising over € 500 million in funds raised by public and private investors.

Launched in 1989, KREAXI's regional activity (Kreaxi Region) has supported more than 260 companies by intervening in the capital of young Rhône-Alpes region companies to finance their early development phases. With € 69 million in funds under management thanks to the support of the Rhône-Alpes Region, Bpifrance, regional banks and industrial groups, Kreaxi Region is in a central position in the financing of seed and creation stages .

It manages a portfolio of about fifty holdings through its three funds (RAC I, RAC II and R2V), with an active team of nine people.

Contact : Gwenaël Hamon, Investment Director, www.kreaxi.com



About Sofimac Partners

Sofimac Partners is an independent multi-regional management company certified by the French financial markets authority (AMF).. Sofimac Partners has been supporting non-listed SMEs in their medium and long-term growth projects over the last 40 years, thanks to a wide range of vehicles, based in Lyon, Paris, Clermont-Ferrand, Orléans, Rennes, Caen and Limoges. (start-up, creation, first development, capital development, transmission capital, turnaround). Involved in a wide range of generalist and technological sectors, and supported by a team of experienced and multidisciplinary investors, Sofimac Partners has accompanied more than 580 SMEs since its creation in 1977. Sofimac Partners benefits from a network of loyal institutional and private subscribers, foremost among whom are Bpifrance and the French government under the Investments for the Future Program. Sofimac Partners now manages over € 700 million in assets, through 35 funds, invested in more than 170 companies.

Contact: François Miceli Managing Partner www.sofimacpartners.com



A JOINT VENTURE BETWEEN CEA AND AMUNDI

A propos de Supernova Invest

Founded in 2017 by the experienced CEA Investissement team, CEA and Amundi, Supernova Invest is a specialist in investment in breakthrough technology start-ups in the life sciences, energy & environment and industry (microelectronics, materials, instrumentation ...). In addition to the investments made with CEA Investissement and Primerage Technologique Investissement, Supernova Invest raised two new funds mid-2017 and now manages € 230 million, from seed to venture capital. Supernova Invest has an active portfolio of some 50 companies.

The investment in Diabeloop was realized with FPCI Supernova 2 (FNA) whose subscribers are Crédit Agricole, the national seed fund managed by Bpi France, CEA, Michelin, Biomérieux, Vinci, EDF, CGG, UDIMEC as well as entrepreneurs and family offices.

Contact: Celia Hart, Partner, celia.hart@supernovainvest.com



Press contacts LIJCOM UNICORP

Lucie Blaise : l.blaise@ljcom.net / +33 (0)1 45 03 60 14

Anne-Laure Brisseau : al.brisseau@ljcom.net / +33 (0)1 45 03 50 36